What benefits are associated with taking icosapent ethyl for secondary prevention?
Taking icosapent ethyl for secondary prevention has been associated with a 25% reduction in the primary endpoint defined as a combination of vascular death, non-fatal MI, non-fatal stroke, coronary revascularization, or unstable angina over 4.9 years (NNT=21) according to a double-blinded, placebo-controlled trial by Bhatt et al. (2019), Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial (REDUCE-IT).